Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Minirin

Phase 3Small molecule

Minirin is one of 18 small molecule programs targeting Enuresis. It is currently in Phase 3.

1

Indications

3

Total Trials

0

Active Trials

17

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

EnuresisPhase 3

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Enuresis

#DrugCompanyPhaseTrials

Indocin

LLife Extension Foundation Inc.

Advil

Pitressin

AAultman Health Foundation

Myrbetriq

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Oxytrol

Circadin

NNeurim Pharmaceuticals Ltd.

Strattera

Minirin

Depacon

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enuresis2 trials

Minirin Versus Oxybutynin for Nocturnal Enuresis in Children

Completed·HHormozgan University of Medical Sciences·Phase 3·NCT02538302·66 enrolled

A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)

Completed· Ferring logo

Ferring·Phase 4·NCT00209261·221 enrolled

Shock1 trial

the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock

Unknown status·AAhmed talaat ahmed aly·Phase 2·NCT04586790·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Minirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Minirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Minirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ferring

Related News